About ixekizumab
Interleukin-17A inhibitor
Used for
- Plaque psoriasis
- Psoriatic arthritis
- Axial spondyloarthritis, including ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
Usual adult dose
Usually injected under the skin every 2 or 4 weeks after initial loading doses; regimen depends on condition.
Usual dose in children
For plaque psoriasis from age 6: weight-based injections every 4 weeks after initial doses. Not established for other pediatric uses.
Common side effects
- Injection-site reactions
- Upper respiratory infections
- Nausea
- Fungal infections
Important warnings
- Serious infections may occur; assess for tuberculosis before treatment.
- Avoid live vaccines during treatment.
- New or worsening inflammatory bowel disease can occur.
- Do not use with another biologic immune-modulating medicine unless directed.
Pregnancy
Human pregnancy data are limited; use requires consideration of potential benefits and risks.
Breastfeeding
It is unknown whether ixekizumab passes into human milk; effects on nursing infants are not established.
Interactions
- Live vaccines may cause infection and should be avoided.
- Other biologic immunosuppressants may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.